Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15216779 | 1.00 | CYP11B1 (0.33) | CYP11B1CYP11B2CYP17A1CYP19A1BACE1 | |
| SCHEMBL15216781 | 1.00 | CYP11B1 (0.33) | CYP11B1CYP11B2CYP17A1CYP19A1BACE1 | |
| SCHEMBL7918290 | 0.83 | TAAR1 (0.38) | CYP11B1CYP11B2BACE1 | |
| SCHEMBL7925882 | 0.83 | CYP11B1 (0.33) | CYP11B1CYP11B2CYP17A1CYP19A1GRM5 | |
| SCHEMBL12203507 | 0.83 | TAAR1 (0.38) | CYP11B1CYP11B2BACE1 | |
| SCHEMBL7924554 | 0.83 | CYP11B1 (0.33) | CYP11B1CYP11B2CYP17A1CYP19A1GRM5 | |
| SCHEMBL12203433 | 0.83 | TAAR1 (0.38) | CYP11B1CYP11B2BACE1 | |
| SCHEMBL7916694 | 0.83 | CYP11B1 (0.33) | CYP11B1CYP11B2CYP17A1CYP19A1GRM5 | |
| SCHEMBL7918096 | 0.82 | GRM5 (0.31) | CYP11B1CYP11B2GRM5 | |
| SCHEMBL7925936 | 0.82 | GRM5 (0.31) | CYP11B1CYP11B2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130225582-A1 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225582-A1 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRA2A | CYP11B1 220/4885CYP11B2 56/4885CYP17A1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.